Navigation Links
Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
Date:9/23/2011

, an FDA-approved antibacterial drug for the treatment of adult patients 18 years of age and older with Clostridium difficile-associated diarrhea (CDAD). Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-Looking Statements

Statements included in this release that are not a description of historical facts are forward-looking statements, including without limitation statements related to the potential regulatory approval of DIFICLIR in the EU, whether the EMA and other regulatory authorities will follow the opinion of the CHMP, the expected timing of a decision on the DIFICLIR MAA filing and the potential availability of DIFICLIR to European CDI patients.  Words such as "believes," "would," "anticipates," "plans," "expects," "may," "intend," "will," and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Astellas or Optimer that any of their plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Astellas' and Optimer's businesses including, without limitation, risks relating to: whether regulatory authorities will review or approve  applications for marketing approval within anticipated timelines or at all, Astellas' ability to successfully commercialize DIFICLIR, if approved, whether DIFICLIR will receive reimbursement from government authorities and other healthcare payors, and other risks detailed in Optimer's filings with the U.S. Securities and Exchange Commission.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Cor
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
2. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
3. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
4. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
6. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
7. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
8. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
10. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
11. Optimer Pharmaceuticals Expands Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  Decision ... colitis (CD/UC) patients eligible for biologic therapy, ... a biologic. Surveyed gastroenterologists cite patients, discomfort ... for low penetration rates, followed by cost-related ... UC patients receiving biologics, Janssen Biotech,s Remicade ...
(Date:9/17/2014)... Sept. 17, 2014  Rebiotix Inc. announced this morning that ... product candidate, RBX2660 (microbiota suspension) will be presented in two ... in Philadelphia from October 8-12. ... the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety ...
(Date:9/17/2014)... , Sept. 17, 2014   OTEMR, Inc. , ... Complete EHR certification, which designates that the software is ... 1 and Stage 2 Meaningful Use measures required to ... Act (ARRA).  ONETOUCH EMR 2.0 was certified on July ... of the National Coordinator-Authorized Certification Body (ONC-ACB) and is ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3
... recommendations for knee and ... hip osteoarthritis, ... MT. LAUREL, N.J., Feb. 19 A newly released set ... worldwide who live in pain due to inconsistent treatment,approaches and confusion ...
... Feb. 19 Joseph F. Finn, Jr.,CPA, the ... announced,today the design of a clinical trial to ... approved antibiotics. Rifalazil, the,most potent anti-chlamydial agent that ... treatment option for Chlamydia STD. The insidious aspect,of ...
Cached Medicine Technology:Osteoarthritis: Which Treatments Work and Which Don't? 2Osteoarthritis: Which Treatments Work and Which Don't? 3ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD 2
(Date:9/18/2014)... September 18, 2014 First Choice ... emergency rooms in the United States, named Douglas J. ... Missouri City-Lakes facility. , “We are pleased to ... medical director of our new Missouri City-Lakes facility,” said ... Choice Emergency Room. , Dr. Harrison received his ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 The Nautilus/ASG ... from active, to medium, and even long term data ... for any length of time. This includes media and ... data. When used together, Nautilus and ASG-Digital Archive will ... content. , "storageFOUNDRY is pleased to work with ...
(Date:9/17/2014)... 2014 The global ablation technologies market ... from 2014 to 2019. Although mature markets (such as ... shares in the ablation technologies market in 2014, the ... CAGR of 12.8% in the next five years.Factors such ... growing number of hospitals and surgical centers, and the ...
(Date:9/17/2014)... 18, 2014 Dr. Shalev is a Texas ... Houston to study at the University of Texas, and graduated ... she realized her real passion lay in dentistry, and she ... the University of Texas Health Science Center at Houston School ... is a member of The Greater Houston Dental Society, and ...
(Date:9/17/2014)... New York, NY (PRWEB) September 18, 2014 ... than 5.9 million tons of medical waste in 2014. ... directly disposed of in landfills along with municipal solid ... the disposal of regulated medical waste (RMW). This includes ... fluids or other potentially infectious materials. As a result ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 3
... Society report outlines 21 challenges and needs for global tobacco ... and expertise needed to reduce the rising tide of tobacco ... are the target of the multinational tobacco industry. The report ... issue of CA: A Cancer Journal for Clinicians . ...
... Genital herpes caused by a reactivation of herpes simplex ... lesion in one specific area of the genital region. ... frequently reactivate throughout the genital tract, an important new ... prevention. Now available online ( http://www.journals.uchicago.edu/doi/abs/10.1086/650302 ), the study ...
... is associated with increased cancer risk. The most ... noted for a common form of liver cancer called ... obesity in mice, researchers at the University of California, ... obesity is tumor-promoting and have obtained evidence that this ...
... Hasbro Children,s Research Center and Hasbro Children,s Hospital researchers ... from The Eunice Kennedy Shriver National Institute of Child ... of asthma on the sleep quality and academic performance ... pediatric researchers, led by Daphne Koinis-Mitchell, PhD, to evaluate ...
... reduce the transmission of influenza-like illness during flu season. ... online ( http://www.journals.uchicago.edu/doi/abs/10.1086/650396 ), published in the Feb. 15 ... In an influenza pandemic, vaccination may not be ... is why scientists need to understand how effective other ...
... The BC Centre for Disease Control has launched ... the pandemic H1N1 flu virus has evolved in British ... months. This project capitalizes on BC,s expertise and ... genomes from circulating influenza viruses collected in British Columbia ...
Cached Medicine News:Health News:Global tobacco report outlines 21 challenges for 21st century 2Health News:Global tobacco report outlines 21 challenges for 21st century 3Health News:Study shows genital herpes virus reactivates widely throughout genital tract 2Health News:Link between obesity and enhanced cancer risk elucidated 2Health News:New research will examine link between childhood asthma, sleep and school performance 2Health News:Study finds face masks and hand hygiene can help limit influenza's spread 2Health News:Genomic surveillance of pandemic H1N1 2
... Ultracentrifuge power for small-volume samples. With ... method of removing chylomicrons (fat particles in ... results for lipemic clarification. Lipemic samples can ... need for sendouts. The easy-to-operate tabletop ...
... Dimension Xpand integrated chemistry system brings ... to the smaller laboratory. A model ... Xpand integrated chemistry system features state-of-the-art ... low-volume testing environment, in a flexible, ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... Dimension clinical chemistry integrated systems combine the ... cartridge, the power of the Multiply and ... the heterogeneous module to meet the challenges ... broad test menus, the systems can meet ...
Medicine Products: